Logo
x

Search

Subscribe Now

lilly

Lilly to Acquire Sigilon Therapeutics for Over $300M to Enhance its Cell Therapy Business for the Treatment of Type 1 Diabetes

Lilly to Acquire Sigilon Therapeutics for Over $300M to Enhance its Cell Therapy Business for the Treatment of Type 1 Diabetes

  • June 30, 2023
Lilly Presented P-II Trial Results of Orforglipron for the Treatments of Adults with Obesity or Overweight at American Diabetes Association

Lilly Presented P-II Trial Results of Orforglipron for the Treatments of Adults with Obesity or Overweight at American Diabetes As...

  • June 26, 2023
Lilly to Acquire Akouos for ~$610M

Lilly to Acquire Akouos for ~$610M

  • October 18, 2022
Lilly Entered into an Exclusive License Agreement with D. E. Shaw Research to Develop and Commercialize DES-7114 for Immunological and Inflammatory Diseases

Lilly Entered into an Exclusive License Agreement with D. E. Shaw Research to Develop and Commercialize DES-7114 for Immunological...

  • June 14, 2022
Lilly Reports Clinical Remission in 50% of Patients Treated with Mirikizumab in P-III (LUCENT-2) Trial for the Treatment of Ulcerative Colitis

Lilly Reports Clinical Remission in 50% of Patients Treated with Mirikizumab in P-III (LUCENT-2) Trial for the Treatment of Ulcera...

  • May 24, 2022
Lilly's Mounjaro (tirzepatide) Receives the US FDA’s Approval for the Treatment of Adults with Type 2 Diabetes

Lilly's Mounjaro (tirzepatide) Receives the US FDA’s Approval for the Treatment of Adults with Type 2 Diabetes

  • May 16, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.